SOBHANI, NAVID

SOBHANI, NAVID  

Dipartimento Universitario Clinico di Scienze mediche, chirurgiche e della salute  

Mostra records
Risultati 1 - 20 di 26 (tempo di esecuzione: 0.016 secondi).
Titolo Data di pubblicazione Autori File
Advances in systemic therapy for malignant mesothelioma: Future perspectives 1-gen-2017 Sobhani, NavidCorona, Silvia PaolaBonazza, DeborahIanza, AnnaRoviello, GiandomenicoCortale, MaurizioGuglielmi, AlessandraZanconati, FabrizioGenerali, Daniele +
Advances in systemic therapy for metastatic breast cancer: future perspectives 1-gen-2017 Corona, S. P.SOBHANI, NAVIDIANZA, ANNAROVIELLO, GIANDOMENICOMUSTACCHI, GIORGIOBORTUL, MARINAZANCONATI, FABRIZIOGENERALI, DANIELE
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 1-gen-2023 Sobhani, NavidAldegheri, GiovanniRocca, AndreaGiudici, FabiolaBottin, CristinaZanconati, FabrizioGenerali, Daniele +
Avelumab in gastric cancer 1-gen-2019 Roviello G.Generali D.De Manzini N.Sobhani N. +
Bevacizumab in small cell lung cancer 1-gen-2017 Roviello, GiandomenicoSobhani, NavidGenerali, Daniele
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 1-gen-2018 Navid SobhaniDaniele GeneraliFabrizio ZanconatiMarina BortulBruna Scaggiante
Corticosteroid switch after progression on abiraterone acetate plus prednisone 1-gen-2020 Roviello G.Sobhani N.Corona S. +
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy 1-gen-2021 Sobhani, NavidGenerali, Daniele +
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 1-gen-2018 Sobhani, NavidGenerali, DanieleRoviello, Giandomenico +
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 1-gen-2018 Sobhani, NavidIanza, AnnaRoviello, GiandomenicoGiudici, FabiolaBortul, MarinaZanconati, FabrizioBottin, CristinaGenerali, Daniele +
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 1-gen-2018 Navid SobhaniDaniele GeneraliFabrizio ZanconatiMarina BortulBruna Scaggiante
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 1-gen-2017 SOBHANI, NAVIDCorona, Silvia PZANCONATI, FABRIZIOGENERALI, DANIELE
Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer 1-gen-2020 Bernocchi O.Sobhani N.Giudici F.Generali D. +
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 1-gen-2017 Sobhani, N.Ianza, A.Roviello, G.Mustacchi, G.Bortul, M.Zanconati, F.Generali, D. +
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study 1-gen-2020 Sobhani, NavidIanza, AnnaBernocchi, OttaviaGiudici, FabiolaGenerali, Daniele +
Lenvatinib for the treatment of renal cell carcinoma 1-gen-2018 Roviello G.Corona S.Generali D.Ianza A.Sobhani N. +
Mutant p53 as an antigen in cancer immunotherapy 1-gen-2020 Sobhani N.Generali D.Li Y. +
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 1-gen-2017 SOBHANI, NAVIDROVIELLO, GIANDOMENICOCorona, S. P.IANZA, ANNAZANCONATI, FABRIZIOGENERALI, DANIELE
P53 antibodies as a diagnostic marker for cancer: A meta-analysis 1-gen-2021 Sobhani N.Roviello G.Generali D. +
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 1-gen-2017 Sobhani, NavidGenerali, DanieleRoviello, Giandomenico